T
0.320
-0.05 (-12.57%)
| Previous Close | 0.366 |
| Volume | 629 |
| Price / Sales | 2.03 |
| Price / Book | 3.09 |
| 52 Weeks Range |
| Operating Margin (TTM) | -9,128.07% |
| Diluted EPS (TTM) | -27.20 |
| Quarterly Revenue Growth (YOY) | 1.80% |
| Current Ratio (MRQ) | 1.81 |
| Operating Cash Flow (TTM) | -30.80 M |
| Levered Free Cash Flow (TTM) | -14.51 M |
| Return on Assets (TTM) | -83.59% |
| Return on Equity (TTM) | -2,331.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Traws Pharma, Inc. | Mixed | - |
AIStockmoo Score
-0.2
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | -2.5 |
| Macro Environment | 0.0 |
| AI Insight | NA |
| Weighted Average | -0.17 |
Select this tab to load the latest available analysis.
|
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 18.86% |
| % Held by Institutions | 31.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Orbimed Advisors Llc | 30 Jun 2026 | 1,203,260 |
| Lynx1 Capital Management Lp | 30 Jun 2026 | 559,470 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |